How to Get Rezdiffra (Resmetirom) in Kentucky

Madrigal Pharmaceuticals produces Rezdiffra (resmetirom), which patients take as an oral tablet once per day. The FDA has approved resmetirom for adults whose MASH (metabolic dysfunction-associated steatohepatitis, previously known as NASH) includes moderate to advanced fibrosis at stage F2 or F3, when combined with dietary changes and physical activity. Resmetirom in its approved formulation is not compounded, and FDA approval does not extend to cirrhosis (F4) or to fatty liver disease without accompanying fibrosis. Kentuckians may obtain resmetirom through in-person appointments with a hepatologist or gastroenterologist, or by telehealth with a prescriber licensed in Kentucky, though actual medication access hinges primarily on documented fibrosis staging and insurance approval rather than geographic location.

Direct answer: A Kentucky patient becomes eligible for a Rezdiffra prescription by having a confirmed MASH diagnosis with documented fibrosis stage F2 or F3 (by liver biopsy or a validated non-invasive test such as FibroScan/vibration-controlled transient elastography), baseline labs including liver enzymes and thyroid function, and no decompensated cirrhosis. Kentucky allows telehealth prescribing of this drug by any provider holding an active Kentucky license, and the medication is dispensed through specialty pharmacy channels rather than typical retail shelves. The rate-limiting step for most patients is commercial prior authorization, not physical drug availability or state law.

What the evidence actually supports, and what does not transfer

Resmetirom's approval rests on a phase 3 randomized trial program (MAESTRO-NASH) that the FDA reviewed before its March 2024 approval. The general shape of the finding, that a meaningfully larger share of resmetirom-treated patients achieved NASH resolution or fibrosis improvement compared with placebo at one year, is well established and summarized on the FDA's own trial snapshot page for the drug. This article does not restate the exact percentage figures from the trial here, because the specific citation carried in earlier versions of this page could not be verified against the primary publication before this review; readers who need the precise numbers for a clinical or insurance decision should pull them directly from the FDA Drug Trials Snapshot for Rezdiffra or the product label rather than relying on this summary.

One boundary condition that generic pages on this topic tend to skip: how you measure treatment response matters. A study of FibroScan measurements taken at two different intercostal spaces in the same patients with MASLD found significant within-individual variability in liver stiffness readings (Pham et al., 2024). That means a single repeat FibroScan a year into treatment can shift meaningfully based on probe placement alone, independent of any real change in fibrosis. A Kentucky patient and prescriber comparing a 12-month FibroScan to baseline should treat a small change as noise and prioritize consistent measurement technique, and ideally the same operator or device, before concluding the drug is or is not working for them.

Pharmacotherapy for NAFLD/MASH is a young field. Before resmetirom, treatment options were limited largely to lifestyle intervention and management of metabolic comorbidities, a gap documented in earlier reviews of the pharmacologic landscape (Sumida & Yoneda, 2021). Emerging tools such as machine-learning models built on routine clinical and lab data are being studied to improve prediction of significant fibrosis in MASLD (2026 analysis), but these are research tools, not yet a substitute for biopsy or elastography in a prior authorization packet, and Kentucky payers are not known to accept them as standalone staging evidence.

Telehealth prescribing in Kentucky

Kentucky permits telehealth prescribing of Rezdiffra by physicians (MD/DO), nurse practitioners, and physician assistants who hold an active Kentucky license or an appropriate interstate compact credential, using a synchronous audio-video visit. This matters in a state where hepatology specialists cluster around Louisville and Lexington and are scarce in much of eastern and western Kentucky.

A telehealth visit generally follows the same clinical pathway as an in-person one: review of imaging or biopsy results, confirmation of fibrosis stage, review of baseline labs, and a contraindication check. Some insurers require the first visit in a course of treatment to be in-person before they will authorize ongoing telehealth follow-ups. That rule varies by plan and changes over time, so confirm it with your specific plan before scheduling rather than assuming telehealth covers the whole process end to end.

Labs and imaging required before starting

The FDA label and most payer prior authorization forms require a baseline workup before resmetirom is prescribed. A prescriber will typically order:

• ALT and AST, since active hepatic inflammation is part of the diagnostic and monitoring picture, and elevated ALT is a common payer requirement
• A thyroid panel (TSH, free T4), because resmetirom acts on the thyroid hormone receptor beta and uncontrolled thyroid disease is a relevant safety consideration
• Hepatitis B and C serology, to rule out viral hepatitis as the primary driver of liver injury
• FibroScan (vibration-controlled transient elastography) or liver biopsy to confirm fibrosis stage F2 or F3
• CBC and INR, to screen for signs of more advanced or decompensated liver disease, since F4 cirrhosis falls outside the current approved indication
• A lipid panel, since resmetirom lowers LDL cholesterol as a secondary effect noted in the trial program

Kentucky has multiple large commercial lab networks and hospital-affiliated labs capable of running the blood panel; turnaround is typically a few business days. FibroScan availability is more limited and concentrated at academic hepatology clinics and some private GI practices. If you need a rough planning estimate, allow one to two weeks for the full diagnostic workup when scheduled efficiently, though this varies by clinic backlog and is not a guarantee.

Who can prescribe it

Physicians, nurse practitioners, and physician assistants can all prescribe Rezdiffra in Kentucky under their respective scope-of-practice rules. Kentucky nurse practitioners have full practice authority after meeting statutory experience requirements, meaning independent prescribing without a mandatory collaborative physician agreement in many circumstances; physician assistants in Kentucky generally practice under a collaborative agreement with a supervising physician. Confirm current scope-of-practice details with the Kentucky Board of Medical Licensure or Board of Nursing, since these rules are updated periodically and a stale summary is not a substitute for the current regulation.

In practice, most Rezdiffra prescriptions originate from hepatologists or gastroenterologists because MASH staging is clinically involved, not because the law restricts prescribing to specialists. A primary care provider comfortable interpreting elastography and managing liver-directed therapy can prescribe and monitor the drug.

Pharmacy access

Rezdiffra is a specialty medication. Most standard retail pharmacy shelves do not stock it; it moves through specialty pharmacy networks that ship directly to patients, and enrollment in a specialty pharmacy is usually coordinated by the prescriber's office as part of the prior authorization workflow. Which specific specialty pharmacy or network handles a given prescription depends on the patient's insurance plan and changes over time, so verify the current in-network specialty pharmacy for your plan rather than assuming a name mentioned elsewhere still applies.

Kentucky-licensed 503A compounding pharmacies exist and can prepare patient-specific prescriptions, but resmetirom is dispensed as a commercially manufactured tablet, and compounding is not a routine pathway for this drug. If a prescriber recommends a compounded version for a specific clinical reason such as a non-standard dose, confirm the pharmacy's current Kentucky Board of Pharmacy license directly with the board rather than taking a pharmacy's self-description at face value.

Prior authorization: the actual bottleneck

Commercial insurers operating in Kentucky generally require prior authorization for resmetirom. A typical PA packet includes documented MASH diagnosis, confirmed fibrosis stage F2 or F3, baseline labs, evidence that the patient has attempted lifestyle modification for a period the payer specifies, and confirmation that decompensated cirrhosis is absent. Exact PA turnaround times differ by insurer and change without notice, so do not plan around a specific number of days without confirming it with the current plan documents or the prescriber's office at the time of submission.

As of this review (May 2026), Kentucky Medicaid managed care does not cover Rezdiffra. This is a coverage decision that can change, and patients or clinics should verify current Medicaid formulary status directly with the Kentucky Department for Medicaid Services or the specific managed care plan before assuming it still applies. If denied by a commercial plan, Kentucky residents have appeal rights, including an external review process administered through the Kentucky Department of Insurance; confirm current review timelines and procedures on that site rather than relying on a fixed day count, since regulatory timelines are updated periodically.

Patients without coverage, or with a high-deductible plan, should ask the prescriber's office about manufacturer copay assistance for commercially insured patients and a separate patient assistance program for uninsured patients who meet income criteria. Exact eligibility thresholds, copay amounts, and program terms are set by the manufacturer and change over time; verify current terms directly with Madrigal Pharmaceuticals or the prescriber's office rather than treating a remembered figure as current.

Monitoring after starting treatment

The FDA label calls for periodic liver function testing during treatment, and thyroid function is typically rechecked given the drug's mechanism. In clinical trial data, gastrointestinal symptoms (diarrhea and nausea) were the most commonly reported side effects, generally described as occurring early in treatment and often improving without stopping the medication; a prescriber should still be contacted for persistent or severe symptoms rather than assuming they will resolve on their own.

As noted above, a single follow-up FibroScan should be interpreted cautiously. Meaningful assessment of fibrosis response over a year typically relies on a consistent measurement approach and clinical correlation with labs and history, not a lone number.

Evidence boundary

Established: Rezdiffra is FDA-approved for MASH with fibrosis stage F2-F3 in adults, dosed once daily, and prescribable and dispensable in Kentucky through licensed physicians, NPs, and PAs, in person or via telehealth. Baseline liver and thyroid labs plus fibrosis staging are required before starting. Prior authorization is the practical gatekeeper for most commercially insured patients, and Kentucky Medicaid does not currently cover the drug.

Plausible but not fully settled for individual patients: How well a single follow-up FibroScan tracks true fibrosis change, given documented measurement variability; how machine-learning fibrosis prediction tools will eventually fit into staging workflows; and how quickly any given Kentucky payer processes a specific PA request.

Not established from the material reviewed here: Exact current wholesale price, exact current copay assistance thresholds, and exact current external-review timelines, since these are volatile figures that change independently of the drug's clinical profile and were not independently reverified for this draft.

Verification checklist: stable facts vs. facts you must reconfirm

Stable, unlikely to change soon (federal approval and clinical mechanics):

• Resmetirom is FDA-approved for MASH with fibrosis F2-F3, not for F4/cirrhosis, taken once daily by mouth
• Baseline labs needed: ALT/AST, TSH and free T4, hepatitis B/C serology, CBC, INR, lipid panel
• Fibrosis staging requires biopsy or a validated non-invasive method (FibroScan/elastography, or MRI-PDFF)
• Physicians, NPs, and PAs can all prescribe it in Kentucky under their respective scope of practice
• Telehealth prescribing is permitted in Kentucky by licensed providers
• A single follow-up elastography reading has known measurement variability and should not be over-interpreted alone

Date-sensitive, reconfirm before relying on it (insurer, state, pharmacy, or price facts):

• Whether your specific plan requires an in-person first visit before telehealth follow-ups
• Which specialty pharmacy is in-network for your plan
• Current Kentucky Medicaid managed care coverage status for resmetirom
• Current PA turnaround time for your specific insurer
• Current external review timelines through the Kentucky Department of Insurance
• Current manufacturer copay card and patient assistance program terms and income thresholds
• Current wholesale or negotiated cash price

Before making a coverage or scheduling decision, confirm each item in the second list directly with the payer, pharmacy, or manufacturer program on the day you need the information, since these details are the ones most likely to have changed since this page was written.